Baltimore, Maryland 21204

  • Suicidal Ideation

Purpose:

This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation


Criteria:

Inclusion Criteria: - Between 18 and 65 years of age at Screening - Diagnosis of Major Depressive Disorder (MDD) - Significant level of suicidal thoughts with active ideation and without immediate intent - Failure to respond to 2 medications in the current episode Exclusion Criteria: - Current or past history of schizophrenia, psychotic disorder, bipolar disorder, borderline personality disorder, etc. - Current alcohol or substance use disorder


NCT ID:

NCT05220410


Primary Contact:

Principal Investigator
Scott Aaronson, MD
Sheppard Pratt Health System

Sam Rudow
Phone: (410) 938-3126
Email: srudow@sheppardpratt.org


Backup Contact:

Email: audrey.shoultz@sheppardpratt.org
Audrey Shoultz
Phone: (410) 938-5263


Location Contact:

Baltimore, Maryland 21204
United States

Sam Rudow
Phone: 410-938-3126
Email: srudow@sheppardpratt.org

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 28, 2022

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.